92 related articles for article (PubMed ID: 12494455)
1. Differential levels of soluble endoglin (CD105) in myeloid malignancies.
Calabrò L; Fonsatti E; Bellomo G; Alonci A; Colizzi F; Sigalotti L; Altomonte M; Musolino C; Maio M
J Cell Physiol; 2003 Feb; 194(2):171-5. PubMed ID: 12494455
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.
Tsirakis G; Pappa CA; Spanoudakis M; Chochlakis D; Alegakis A; Psarakis FE; Stratinaki M; Stathopoulos EN; Alexandrakis MG
Eur J Intern Med; 2012 Jun; 23(4):368-73. PubMed ID: 22560388
[TBL] [Abstract][Full Text] [Related]
3. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.
Musolino C; Alonci A; Bellomo G; Loteta B; Quartarone E; Gangemi D; Massara E; Calabrò L
Eur J Haematol; 2004 Jun; 72(6):416-9. PubMed ID: 15128420
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
5. Differential kinetics of plasma CD105 and transforming growth factor beta expression early in human acute pancreatitis.
Jamdar S; Al-Mowallad AF; Kumar S; Siriwardena AK
Pancreas; 2006 Mar; 32(2):152-8. PubMed ID: 16552334
[TBL] [Abstract][Full Text] [Related]
6. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer's disease patients.
Juraskova B; Andrys C; Holmerova I; Solichova D; Hrnciarikova D; Vankova H; Vasatko T; Krejsek J
J Nutr Health Aging; 2010 Nov; 14(9):758-61. PubMed ID: 21085906
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.
Blaha M; Cermanova M; Blaha V; Jarolim P; Andrys C; Blazek M; Maly J; Smolej L; Zajic J; Masin V; Zimova R; Rehacek V
Atherosclerosis; 2008 Mar; 197(1):264-70. PubMed ID: 17540382
[TBL] [Abstract][Full Text] [Related]
10. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Postiglione L; Di Domenico G; Caraglia M; Marra M; Giuberti G; Del Vecchio L; Montagnani S; Macri M; Bruno EM; Abbruzzese A; Rossi G
Int J Oncol; 2005 May; 26(5):1193-201. PubMed ID: 15809709
[TBL] [Abstract][Full Text] [Related]
11. Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.
Vidal AC; Duong F; Howard LE; Wiggins E; Freedland SJ; Bhowmick NA; Gong J
Anticancer Res; 2020 Mar; 40(3):1459-1462. PubMed ID: 32132043
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.
Li C; Wilson PB; Levine E; Barber J; Stewart AL; Kumar S
Int J Cancer; 1999 Apr; 84(2):155-9. PubMed ID: 10096248
[TBL] [Abstract][Full Text] [Related]
13. TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1.
Li C; Guo B; Ding S; Rius C; Langa C; Kumar P; Bernabeu C; Kumar S
Anticancer Res; 2003; 23(2B):1189-96. PubMed ID: 12820370
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
Li C; Guo B; Wilson PB; Stewart A; Byrne G; Bundred N; Kumar S
Int J Cancer; 2000 Mar; 89(2):122-6. PubMed ID: 10754488
[TBL] [Abstract][Full Text] [Related]
15. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
17. The TGF beta receptor endoglin in systemic sclerosis.
Dharmapatni AA; Smith MD; Ahern MJ; Simpson A; Li C; Kumar S; Roberts-Thomson PJ
Asian Pac J Allergy Immunol; 2001 Dec; 19(4):275-82. PubMed ID: 12009077
[TBL] [Abstract][Full Text] [Related]
18. Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells.
Warrington K; Hillarby MC; Li C; Letarte M; Kumar S
Anticancer Res; 2005; 25(3B):1851-64. PubMed ID: 16158917
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
[TBL] [Abstract][Full Text] [Related]
20. Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells.
Zhang H; Shaw AR; Mak A; Letarte M
J Immunol; 1996 Jan; 156(2):564-73. PubMed ID: 8543807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
